NC Company Will Soon Announce Results of Major Depressive Disorder Study

North Carolina based Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled more than 300 patients with major depressive disorder. Arrivo expects top-line data in early Q4 2022. The study is a multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of SP-624 in the treatment of adults with major depressive disorder. The trial is being conducted across 39 clinical trial sites in the United States with a total of 319 patients enrolled.

Author: Mike Jackson